From an innovative coating for joint replacements, to a promising drug for the painful inflammatory disease scleroderma, 11 new biomedical ideas that emerged from research across Michigan have just gotten funding that could help them make the leap from lab to patient care.
Over $2 million in funding has just flowed to the teams developing these concepts from the Michigan Translational Research and Commercialization for Life Sciences Innovation Hub. MTRAC, as it’s known, is co-managed by the University of Michigan Medical School and Office of Research with funding from U-M and the Michigan Economic Development Corporation.
[wpipa id=”14165″]
Projects from across the state were selected for funding by MTRAC’s Innovation Hub team, to accelerate their paths to market, bringing them one step closer to ultimately helping patients and their families.
Finalists for the funding, including teams from U-M, Michigan State University, Michigan Technological University, Beaumont Health System, and Henry Ford Health System, presented project proposals to the MTRAC Oversight Committee at their annual meeting in downtown Ann Arbor in early January.
Those selected for funding range from an antibacterial coating for orthopedic implants to a novel nano-vaccine technology to a potential next-generation cancer therapeutic. Award amounts range from $130,000 to $260,000 per project, supporting mid-stage product development activities that are critical steps on the path to market.
